<DOC>
	<DOC>NCT02160054</DOC>
	<brief_summary>To evaluate the safety and efficacy of Graceptor ® in patients with kidney transplantation when converted from cyclosporine</brief_summary>
	<brief_title>Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients who are converted to Graceptor® from cyclosporine in the maintenance phase after kidney transplantation. Patients who meet one or more of following criteria 1. Decrease in kidney function: GFR (or eGFR) less than 60 mL/min, or investigator's decision 2. Hypertension: systolic/diastolic blood pressure 130/80 mmHg or more or treatment with an antihypertensive drug 3. Hyperlipidaemia: LDL cholesterol 120 mg/dL or more, or treatment with an antihyperlipidemic drug 4. Rejection: antibody mediated rejection by Banff classification borderline changes or more severe, or investigator's decision 5. Other adverse events and patients who cannot continue cyclosporine treatment based on investigator's decision</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>tacrolimus</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>Graceptor®</keyword>
	<keyword>kidney transplantation</keyword>
</DOC>